CANADA (HEALTH CANADA)
|
|
- Bryce Gaines
- 6 years ago
- Views:
Transcription
1 1 GMP GAZETTE TM May 2016 HPFBI CANADA (HEALTH CANADA) No updates NNHPD NHPs Final Monograph for Antiseptic Skin Cleanser Who`s Affected? Companies seeking NPN or DIN for topical antiseptic hand cleansers intended for domestic/personal care use. Official monograph for Antiseptic Skin Cleanser for domestic/personal care use What`s the Impact? Stakeholders must be aware of the content of this Monograph to ensure their PLAs are accepted.
2 2 Posted Date: February 09, 2016 Effective Date: February 09, 2016 The Non Prescription and Natural Health Products Directorate is moving new physical and mailing addresses Who`s Affected? All companies seeking product or site license from NNHPD. For the following, refer to the addresses listed at"contact Us" : Mail / Courier of Product License Applications Mail / Courier of Site License Applications Clinical Trial Applications Trading Partner Enrolment Packages Consultations Product Classifications General Enquiries Technical Issues and/or Errors with Forms/Databases What`s the Impact? NNHPD will not be responsible for the applications sent to the wrong address after May 06, Both physical and addresses have been updated. Posted Date: April 14, 2016 Effective Date: May 06, 2016 DISINFECTANTS
3 3 No updates NON PRESCRIPTION DRUGS No Updates TPD COSMETICS No updates DRUGS Revised: Guidance Document: Preparation of Drug Regulatory Activities in the "Non ectd Electronic Only" Format Who`s Affected? All drug manufacturers performing regulatory submissions of any purpose (Defined in Scope and Application section of the guidance document) This Document:
4 4 Is a revision to the Guidance Document: Preparation of Drug Regulatory Activities in the "Non ectd Electronic Only" Format, published in September 2015, and now includes Division 8 drugs and Clinical Trial regulatory activities in "non ectd electronic only" format Contains the provision for electronics submission of the regulatory activity/transaction where the ectd format is not accepted by Health Canada Outlines the dates for phasing out paper submissions for certain regulatory purposes of Division 1, Division 5, Division 8, DSUR, PV Data,, Level III and DMF Details the structure and content of the document for the applicable regulatory activity What`s the impact? Paper will no longer be accepted as of June 1st, 2016 for Division 5 and Division 8. By March 31, 2016, all existing DMFs in paper format must be replaced by a complete DMF conversion in an electronic only format. Posting Date: February 03, 2016 Q9: Quality Risk Management Who s affected? All GMP manufacturers engaged with development, manufacturing, distribution, and the inspection and submission/review processes throughout the lifecycle of drug substances, drug (medicinal) products, biological and biotechnological products (including the use of raw materials, solvents, excipients, packaging and labeling materials in drug (medicinal) products, biological and biotechnological products). Health Canada has announced the adoption of ICH Q9: Quality Risk Management. In order to fulfill the commitment to internationally harmonized practices, Health Canada has adopted yet another ICH guidance document. In the circumstances where subject matter of current Health Canada guidances may not be entirely consistent with those of the ICH, Health Canada adopted ICH guidelines will take precedence. What`s the Impact? While the current Health Canada requirements still remain in effect, Health Canada will acknowledge the implementation of the Risk Management as per ICH Q9 as equivalent to their own. Health Canada has committed to eliminate any discrepancies via amendment and/or withdrawal. Posted Date: February 05, 2016
5 5 Effective Date: February 05, 2016 Q8(R2): Pharmaceutical Development Who s affected? Companies preparing GMP Drug Product and Biological Product regulatory submissions ICH Q8 (R2) guideline describes the suggested contents for 3.2.P.2 section of a regulatory submission in the ICH M4 Common Technical Document (CTD) format. In order to fulfill the commitment to an internationally harmonized practices, Health Canada has adopted yet another ICH guidance document. In the circumstances where subject matter of current Health Canada guidances may not be entirely consistent with those of the ICH, Health Canada adopted ICH guidelines will take precedence. What`s the Impact? While the current Health Canada requirements still remain in effect, the Health Canada will acknowledge the use of ICH Q8(R2): Pharmaceutical Development, for submission purposes, as equivalent to their own. Health Canada has committed to eliminate any discrepancies via amendment and/or withdrawal. Posted Date: February 11, 2016 Effective Date: February 11, 2016 Q11: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities) Who s affected? Companies preparing GMP Drug Substance and Biological Entities regulatory submissions ICH Q11 describes developing and understanding the manufacturing process of the drug substance It also has guidance on what information should be provided in Module 3 of the Common Technical Document (CTD) Sections 3.2.S S.2.6 (ICH M4Q).
6 6 In order to fulfill the commitment to internationally harmonized practices, Health Canada has adopted yet another ICH guidance document. In the circumstances where subject matter of current Health Canada guidances may not be entirely consistent with those of the ICH, Health Canada adopted ICH guidelines will take precedence. What`s the Impact? While the current Health Canada requirements still remain in effect, Health Canada will acknowledge the use of ICH Q11: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities) for submission purposes, as equivalent to their own. Health Canada has committed to eliminate any discrepancies via amendment and/or withdrawal. Posted Date: February 11, 2016 Effective Date: February 11, 2016 Q10: Pharmaceutical Quality System Who s affected? Companies developing and manufacturing pharmaceutical drug substances (APIs) and drug products, biotechnology and biological products ICH Q10 describes one comprehensive model for an effective pharmaceutical quality system which can be implemented throughout the different stages of product lifecycle. In order to fulfill the commitment to internationally harmonized practices, Health Canada has adopted yet another ICH guidance document. In the circumstances where subject matter of current Health Canada guidances may not be entirely consistent with those of the ICH, Health Canada adopted ICH guidelines will take precedence. What`s the Impact? While the current Health Canada requirements still remain in effect, Health Canada will acknowledge the use of ICH Q10: Pharmaceutical Quality System throughout the product lifecycle, as equivalent to their own. Health Canada has committed to eliminate any discrepancies via amendment and/or withdrawal. Posted Date: February 16, 2016 Effective Date: February 16, 2016
7 7 Notice: Guidance Document: Tamper resistance Formulations of Opioid Drug Products Who`s Affected? Sponsors seeking to obtain approval for controlled release opioid drug formulations with tamper resistant properties. This guidance: Provides guidance to sponsors seeking Notice of Compliance (NOC) with the claim of a tamper resistant formulation containing opioid drug products. Includes criteria and data requirement for pre market studies Has information regarding what is required for the Product Monograph What`s the impact? Guidance documents are administrative instruments not having force of law and, as such, allow for flexibility in approach. Alternate approaches, supported by adequate justification, should be discussed in advance with the relevant program area to avoid the possible finding that applicable statutory or regulatory requirements have not been met. Posted Date: March 30, 2016 Effective Date: March 30, 2016 MEDICAL DEVICES Final Guidance Document: Labelling of In Vitro Diagnostic Devices Medical Devices Who`s Affected? Companies manufacturing, packaging, labelling and marketing in vitro diagnostic devices (IVDDs) This document clarifies the labelling requirements in Sections of the Medical Devices Regulations SOR/ Information was added on e labelling and labelling of smaller containers and blood glucose monitoring systems. What`s the impact? This document replaces the Draft Guidance for the Labelling of In Vitro Diagnostic Devices issued on July 16, 1998 and is effective from April 22, 2016.
8 8 Posting Date: April 22, 2016 Effective Date: April 22, 2016 Consultation Proposed Changes to the Therapeutic Products Directorate's List of Recognized Standards for Medical Devices Who`s Affected? Companies manufacturing, packaging, labelling and marketing Medical Devices Health Canada has posted this Notice of Consultation to provide an opportunity to comment on proposed changes to the therapeutic products directorate`s list of recognized standards for medical devices. The proposed changes consist of: 1) Seven new standards to be added; 2) Two new editions of currently recognized standards added alongside existing versions, with a transition period of three years from the standard's publication date. These standards are: a) IEC :2015 Safety requirements for electrical equipment for measurement, control and laboratory use Part 2 101: Particular requirements for in vitro diagnostic (IVD) medical equipment b) IEC :2014 Medical electrical equipment Part 1 2: General requirements for basic safety and essential performance Collateral Standard: Electromagnetic disturbances Requirements and tests 3) Nine new editions of currently recognized standards to replace previous editions; 4) Two standards to be removed. What`s the impact? This consultation is open for comments and suggestions until July 2, Refer to the posting for contact numbers and addresses. Posting Date: May 03, 2016
9 9 CDER USA (FDA) DRUGS Draft Guidance for Industry, Data Integrity and Compliance With Current Good Manufacturing Practice Guidance for Industry Who s affected? All Companies involved in any cgmp operations associated with Drug Products, Materials, Biologics and Medical Devices in the United States of America This guidance documents provides much awaited clarity on the FDA`s expectation on Data Integrity and Compliance issues cited during numerous FDA issued 483s in recent years. The key highlights are; o Definition of Data Integrity o Definition of Static and Dynamic Data o Work Flow Validation Expectations for the computer system o cgmp Computer System Restriction Expectations o Audit Trail Review Who, What, How, When o Testing into Compliance with samples usage for System Suitability, Trial, Test, Equilibration Runs What`s the Impact? The draft guidance is open for comments until June 14, Comments can be submitted online, using the following link D Posting Date: April 25, 2016
10 10 Completeness Assessments for Type II API DMFs Under GDUFA Guidance for Industry Who`s affected? Holders of Type II API DMFs that are or will be referenced in an abbreviated new drug application (ANDA), an amendment to an ANDA, a prior approval supplement (PAS) to an ANDA, or an amendment to a PAS (generic drug submissions). This guidance makes recommendations about the information that should be included in DMF to facilitate FDA`s mandatory Completeness Assessment (CA) introduced with Generic Drug User Fee Amendments (GDUFA) in o Completeness Assessment by FDA What, How and Why o Outcomes and Interpretation of the CAs What`s the impact? This guidance document is not a legal requirement, it just describes the FDA`s thinking on the topic and hence it should viewed as a recommendation only unless specific regulatory or statutory requirements are cited. Posting Date: February 16, 2016 Who`s affected? All companies submitting application for Biosimilar Products under section 351(k) of the PHS This draft guidance: Provides recommendations on the development of draft labels of prescribing information (package insert) for submission of Biosimilar Products. o When to use Biosimilar Product Name, When to use Reference Product Name, When to use Core name etc. o Specific recommendation on the content of the package insert Includes instructions for initial or revised label submissions What`s the Impact? The draft guidance is open for comments until June 3, Comments can be submitted online use following link D Posting Date : April 04, 2016
11 11 CBER VACCINES & BIOLOGICS Draft Guidance for Industry, Data Integrity and Compliance With Current Good Manufacturing Practice Guidance for Industry Who s affected? All Companies involved in any cgmp operations associated with Drug Products, Materials, Biologics and Medical Devices in the United States of America This guidance documents provides much awaited clarity on the FDA`s expectation on Data Integrity and Compliance issues cited during numerous FDA issued 483s in recent years. The key highlights are; o Definition of Data Integrity o Definition of Static and Dynamic Data o Work Flow Validation Expectations for the computer system o cgmp Computer System Restriction Expectations o Audit Trail Review Who, What, How, When o Testing into Compliance with samples usage for System Suitability, Trial, Test, Equilibration Runs What`s the Impact? The draft guidance is open for comments until June 14, Comments can be submitted online, using the following link D Posting Date: April 25, 2016
12 12 Completeness Assessments for Type II API DMFs Under GDUFA Guidance for Industry Who`s affected? Holders of Type II API DMFs that are or will be referenced in an abbreviated new drug application (ANDA), an amendment to an ANDA, a prior approval supplement (PAS) to an ANDA, or an amendment to a PAS (generic drug submissions). This guidance makes recommendations about the information that should be included in DMF to facilitate FDA`s mandatory Completeness Assessment (CA) introduced with Generic Drug User Fee Amendments (GDUFA) in o Completeness Assessment by FDA What, How and Why o Outcomes and Interpretation of the CAs What`s the impact? This guidance document is not a legal requirement, it just describes the FDA`s thinking on the topic and hence it should viewed as a recommendation only unless specific regulatory or statutory requirements are cited. Posting Date: February 16, 2016 CFSAN COSMETICS No updates DIETARY SUPPLEMENTS
13 13 No updates CDRH MEDICAL DEVICES No Updates USP (GENERAL CHAPTERS) USP Publishes new General Chapter <800> Hazardous Drugs Handling in Healthcare Settings Who`s affected? All healthcare personnel (i.e., physicians, nurses, veterinarians, pharmacists and technicians) and all healthcare facilities where hazardous drugs are handled or manipulated, including their storage and distribution. Primary Goal is to prevent and/or limit exposure of hazardous drug to healthcare personnel and/or patients. The standard builds upon several previous publications, including the NIOSH Alert Preventing Occupational Exposure to Antineoplastic and Other Hazardous Drugs in Health Care Settings; OSHA Guidelines; ASHP Guidelines on Handling Hazardous Drugs; and the Oncology Nursing Society (ONS) Safe Handling of Hazardous Drugs. What`s the impact? The standard was released on February 01, 2016 and the impacted facilities have until July 01, 2018 to comply with the requirements. The requirements are included as General Chapter <800> in the first supplement of USP 39 NF 34 released on February 01, 2016.
14 14 Published on: February 01, 2016 Effective Date: February 01, 2016
CANADA (HEALTH CANADA)
LEADERS 1 THE GMP GAZETTE TM February 2015 HPFBI CANADA (HEALTH CANADA) Blood Establishment Registration Application: Form and Instructions - (FRM-0353) Who s affected? Anyone who plans to perform the
More informationCANADA (HEALTH CANADA)
1 GMP GAZETTE TM January 2016 HPFBI CANADA (HEALTH CANADA) NNHPD NHPs Notice to Stakeholders Regarding Site Licensing Update Who s affected? Manufacturers, packagers, labellers, importers, and distributors
More informationCANADA (HEALTH CANADA)
1 GMP GAZETTE TM March 2015 HPFBI CANADA (HEALTH CANADA) Notice, Re: Regulatory Decision Summaries and Submissions Under Review Who s affected? Manufacturers of prescription drugs (pharmaceuticals and
More informationEstablished Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry
Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationCGMP Requirements for Investigational Products
PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health
More informationSaudi FDA Drug Approval Process. Dr. Mohammed A. Alquwaizani Consultant- Chief of the scientific office Saudi Food and Drug Authority
Saudi FDA Drug Approval Process Dr. Mohammed A. Alquwaizani Consultant- Chief of the scientific office Saudi Food and Drug Authority Objective Describe the drug regulation practice in Saudi Arabia and
More informationINSTRUCTIONS FOR FILLING OUT FORM FDA 1571 INVESTIGATIONAL NEW DRUG APPLICATION (IND)
INSTRUCTIONS FOR FILLING OUT FORM FDA 1571 INVESTIGATIONAL NEW DRUG APPLICATION (IND) (The field numbers below correspond to the numbered boxes on the Form FDA 1571) Field 1: NAME OF SPONSOR The sponsor
More informationINSTRUCTIONS FOR FILLING OUT FORM FDA 1571 INVESTIGATIONAL NEW DRUG APPLICATION (IND)
INSTRUCTIONS FOR FILLING OUT FORM FDA 1571 INVESTIGATIONAL NEW DRUG APPLICATION (IND) (The field numbers below correspond to the numbered boxes on the Form FDA 1571) Field 1: NAME OF SPONSOR The sponsor
More informationStatus of Food and Drug Administration Programs and Activities During the Current Government Shutdown
Status of Food and Drug Administration Programs and Activities During the Current Government Shutdown Agency-Wide FDA can perform activities necessary to address imminent threats to the safety of human
More informationThe procedure of Certification of Suitability to the Monographs of the European Pharmacopoeia (CEP) and the EDQM Inspection Programme
18/10/2016 The procedure of Certification of Suitability to the Monographs of the European Pharmacopoeia (CEP) and the EDQM Inspection Programme Chinese & European Pharmacopoeias Workshop 17 October 2016
More informationGuidance for Industry
Guidance for Industry Cooperative Manufacturing Arrangements for Licensed Biologics Additional copies of this guidance are available from the Office of Communication, Training and Manufacturers Assistance
More informationGuidance for Industry
Guidance for Industry Cooperative Manufacturing Arrangements for Licensed Biologics DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationCATEGORY Advertising. CATEGORY Biopharmaceutics. CATEGORY Biosimilarity
Guidance Agenda: New & Revised Draft Guidances CDER is Planning to Publish During Calendar Year 2015 (See the Good Guidance Practices (GGPs) regulation on this Web page or 21 CFR 10.115 for details about
More informationFood and Drug Administration (FDA) 101
Food and Drug Administration (FDA) 101 What is the Food and Drug Administration (FDA)? The FDA is an agency within the U.S. Department of Health and Human Services that is responsible for protecting the
More informationUSP Standards for Ancillary Materials
Quality Standards for Medicines, Supplements, and Food Ingredients throughout the World USP Standards for Ancillary Materials 8 th Annual Somatic Cell Therapy Symposium September 22-24 2008 Fouad Atouf,
More informationOverview of global registration of vaccines
Overview of global registration of vaccines by Dr. Nora Dellepiane Workshop: Global Registration and Vaccine Shortage Taipei, Taiwan 6 to 10 March 2017 Outline of the presentation The objective of medicines
More informationCMC Considerations for 505(b)(2) Applications. Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C.
CMC Considerations for 505(b)(2) Applications Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C. October 2011 1 Introduction Outline Brief overview of FDA drug approval pathways
More informationSenior Regulatory Affairs Executive AREAS OF EXPERTISE
Senior Regulatory Affairs Executive AREAS OF EXPERTISE More than fifteen years experience in vaccines, pharmaceuticals, biotechnology, and combination device products. Experience in regulatory strategy
More informationThe Deemed to be a License Provision of the BPCI Act Questions and Answers Guidance for Industry
The Deemed to be a License Provision of the BPCI Act Questions and Answers Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
More informationControl strategy and validation. Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA
Control strategy and validation Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA 1 Disclaimer The views and opinions expressed in this presentation are those of the speaker and should not
More informationLatest Trend of Drug Quality in Korea In-Kyu Kim, Ph.D. Division Director Drug Evaluation Department
Latest Trend of Drug Quality in Korea 2008. 4.14 In-Kyu Kim, Ph.D. Division Director Drug Evaluation Department Contents Status of KFDA CMC, GRP and CTD DMF GMP Quality Control on the market International
More informationFDA Guidance and Current Experience with New Drug Submissions
FDA Guidance and Current Experience with New Drug Submissions Danae Christodoulou, Ph.D. CDER/OPQ Office of New Drug Products This presentation reflects the views of the author and should not be construed
More informationDRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Document issued on: July 14, 2011
Draft Guidance for Industry and Food and Drug Administration Staff In Vitro Companion Diagnostic Devices DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Document issued
More informationDrug Products, Labeling, and Packaging
442 Pharmaceutical Industry: Drug Products, Labeling, and Packaging Positions Drug Products, Labeling, and Packaging Ready-to-Administer Packaging for Hazardous Drug Products Intended for Home Use (1711)
More informationFlexible and Pending Monographs
Flexible and Pending Monographs USP Approaches to Accommodate Multiple Approved Products Doreen McDonald Senior National Account Manager U.S. Pharmacopeial Convention Flexible Monographs: Background From
More informationRegulations of Biologics in Taiwan
Regulations of Biologics in Taiwan Churn-Shiouh Gau, Ph.D. Executive Director, Taiwan 2013/2/13 1 Outlines Regulation of Drugs in Taiwan - Organizations Regulations for Marketing Approval for Drugs including
More informationEU and FDA GMP Regulations: Overview and Comparison
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational
More informationCDER 2016 Actions and 2017 Priorities. Richard Moscicki Deputy Center Director for Science Operations, CDER, FDA
CDER 2016 Actions and 2017 Priorities Richard Moscicki Deputy Center Director for Science Operations, CDER, FDA Disclosure My comments today are mine and do not necessarily represent the views of the US
More informationGlossary of Abbreviations
Glossary of Abbreviations ANDA APhA Abbreviated New Drug Application American Pharmaceutical Association API Active Pharmaceutical Ingredient BA/BE Bioavailability/Bioequivalence BE Bioequivalence Bio
More informationQuestion-based Review (QbR)
Question-based Review (QbR) Rebecca L. Owen, Ph.D. Team Leader, Feed/Topical Team Division of Manufacturing Technologies ONADE/CVM/FDA Outline Background on CMC Filing Requirements What is QbR? QbR at
More informationOverview of USP Activities and How to Get Involved
Overview of USP Activities and How to Get Involved Ravi Ravichandran, Ph.D. Principal Scientific Liaison, Chemical Medicines United States Pharmacopeia Outline Introduction to the USP USP Standard Setting
More informationAuditor General of Canada to the House of Commons
2011 Report of the Auditor General of Canada to the House of Commons FALL Chapter 4 Regulating Pharmaceutical Drugs Health Canada Office of the Auditor General of Canada The Fall 2011 Report of the Auditor
More informationQ&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document
Q&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document March 2017 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 ICH Q7 - Questions
More informationPharmacist Rana Musa Al-ali (Malkawi) MSc (Pharmaceutical Quality Assurance) Registration Department/JFDA
Pharmacist Rana Musa Al-ali (Malkawi) MSc (Pharmaceutical Quality Assurance) Registration Department/JFDA 1 2 ND MENA Regulatory Conference On Bioequivalence, Biowaivers, Bioanalysis, Dissolution & Biosimilars
More informationJeff Yuen and Associates, Inc. PO Box 6026 Orange, CA Zenaida Power Regulatory Expertise:
Regulatory Expertise: Pharmaceuticals: Sterile-Liquids, Non-Sterile Liquids, Solid Oral Dosage Form, Parenterals, Antibiotics, APIs/Bulk Chemicals, Creams & Ointments Medical Devices: Implantable / Active
More informationSynopsis: FDA Process Validation Guidance
Synopsis: FDA Process Validation Guidance This synopsis is a comparison of the draft version 2008 and the final version 2011 of the U.S. FDA Guidance Process Validation: General Principles and Practices.
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationSTIMULI TO THE REVISION PROCESS
Page 1 of 6 STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts USP's Nomenclature Initiatives Angela G. Long, M.S.; Andrzej
More informationRegulatory Guidance How to Market a Biological (Schedule D) Drug
Health Santé Canada Canada General Overview Regulatory Guidance How to Market a Biological (Schedule D) Drug This fact sheet provides general information about the approval and sale of Biological (Schedule
More informationHealth Canada s NHP Vigilance Activities
Health Canada s NHP Vigilance Activities Canadian Health Food Association (CHFA) East October 3, 2013 Scott Sawler Director General Marketed Health Products Directorate Overview NHP Program & MHPD Activities
More informationNew and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 2)
New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 2) Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and
More informationDrug-Device Combination Product Development: INDs for Device Companies
Drug-Device Combination Product Development: INDs for Device Companies David Armbruster Global Program Manager April 24, 2013 Drug-Device Combination Product Development -or- The scenic route to an IND
More informationHow to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER
How to Avoid Common Deficiencies in INDs and NDAs Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER 1 Structure of FDA Office of Commissioner Chief Scientist FOODS Medical Products & Tobacco
More informationGuidance for Industry ANDAs: Stability Testing of Drug Substances and Products
Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
More informationRegulatory Requirements & Recent Changes, including expectations for APIs & IMPs
Regulatory Requirements & Recent Changes, including expectations for APIs & IMPs Neil Raw - GMP Inspector Richard Andrews - Operations Manager 11 th November 2008 Programme: Regulatory Requirements Neil
More informationConducted Under an IND to Support a
Using Foreign Clinical Trial Data not Conducted Under an IND to Support a US Application PDA Midwest Chapter Meeting March 15, 2018 2013 2017 Regulatory Compliance Associates Inc. All Rights Reserved.
More informationAnalytical Procedures and Methods Validation for Drugs and Biologics
Final Guidance for Industry Analytical Procedures and Methods Validation for Drugs and Biologics Analytical procedures and Method Validation June 21, 2016 Lokesh Bhattacharyya Chief, LACBRP/DBSQC OCBQ/CBER/FDA
More informationComparative Study of Regulatory Requirements for Biologics Filing in United States and European Union
Comparative Study of Regulatory Requirements for Biologics Filing in United States and European Union Mr. Shashi Kumar Yadav Assistant Professor Sri Indu Institute of Pharmacy Hyderabad Outline Introduction
More informationANDA ANDA APPROVAL
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring, MD 20993 ANDA 206388 ANDA APPROVAL Teva Pharmaceuticals USA, Inc. 425 Privet Rd. Horsham, PA 19044 Attention: Rich Leone
More informationJournal of Chemical and Pharmaceutical Research
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(6):88-98 Conduct of Inspections for Pharmaceutical Manufactures
More informationKINGSMANN CARE GROUP
PHARMA CONSULTANTS KINGSMANN CARE GROUP KINGSMANN CONSULTANCY SERVICES Thank you for taking interest in Kingsmann Consultancy Services. Kingsmann Consultancy (KC) is a leading business development-consulting
More informationPhase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017
Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/
More informationSec Short title; finding. Sec Authority to assess and use drug fees. Sec Reauthorization; reporting requirements.
H.R. 2430, FDA Reauthorization Act of 2017 Section 1. Short Title. This Act may be cited as the FDA Reauthorization Act of 2017. Section 2. Table of Contents Table of Contents TITLE I: FEES RELATING TO
More informationIVT Laboratory Week Jerry Lanese. Ph.D. The Lanese Group, Inc The Lanese Group, Inc.
IVT Laboratory Week-2015 Jerry Lanese Ph.D. The Lanese Group, Inc. 1 Name Job What brought you here. 2 FDA interest in Quality Metrics What are Quality Metrics Quality metrics FDA will request The impact
More informationHuman Subject Protection; Acceptance of Data From Clinical Investigations for Medical
This document is scheduled to be published in the Federal Register on 02/21/2018 and available online at https://federalregister.gov/d/2018-03244, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon
ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon 9 November 2016 Disclaimer The views and opinions expressed in this presentation are those of the author
More informationDRAFT Guidance Document for Industry - Preparation and Submission of Summary Reports for Marketed Health Products
DRAFT Preparation and Submission of Summary Reports for Marketed Health Products Annual Summary Reports and Issue-Related Summary Reports (effective date: Month dd, yyyy) Health Canada is the federal department
More informationRaw Material and Manufacturer Approval Procedure
Raw Material and Manufacturer Approval Procedure National Health Regulatory Authority (NHRA) Kingdom of Bahrain May 2018 Version 1 1 1. Introduction This document is meant to provide assistance to industry
More informationHarmonizing FDA Regulation and the Practice of Pharmacy: Challenges and Opportunities. Plus an update on PET Drug User Fees
Harmonizing FDA Regulation and the Practice of Pharmacy: Challenges and Opportunities Plus an update on PET Drug User Fees Michael Nazerias - Vice President, RA/QA PETNET Solutions, Inc. (a Siemens Company)
More informationHealth Canada's Experience When Implementing the ICH Q3D Elemental Impurity Guidance for NDSs and ANDSs
Health Canada's Experience When Implementing the ICH Q3D Elemental Impurity Guidance for NDSs and ANDSs Alison Ingham PQRI/USP Elemental Impurities workshop 9 November 2016 Introduction Health Canada is
More informationSeptember 12, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
September 12, 2013 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: : Draft Guidance for Industry on Pediatric Study Plans: Content
More informationDIFFERING CMC REQUIREMENTS: US AND EU
WHITEPAPER DIFFERING CMC REQUIREMENTS: US AND EU Torsten Schnetgoeke M.Sc. Senior Manager, Regulatory Affairs torsten.schnetgoeke@pharmalex.com Torsten joined PharmaLex in 2015 as a Senior Manager in Regulatory
More informationQUALITY AGREEMENT. The following Agreement has been concluded between
QUALITY AGREEMENT The following Agreement has been concluded between LLC LABORATORIES The contract laboratory and service provider 1625 Trinity Dr., Unit 11 Mississauga, Ontario Canada L5T 1W9 Hereinafter
More informationGMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides
FDA cgmp cgmp Guide Drugs 21 CFR 210 cgmp Guide Drugs 21 CFR 211 cgmp Guide Medical Device 21 CFR 808, 812, 820 cgmp Guide Biologics 21 CFR 600, 606, 610 Guideline List Human Drugs Guideline List Biologics
More informationVaccine Prequalification Dossier
Vaccine Prequalification Dossier Introduction The current process for prequalification of vaccines states that once a product is eligible for prequalification evaluation the manufacturer must submit a
More informationCMC Strategy Forum Japan November Piyanan Boonprasirt Bureau of Drug Control Thailand Food and Drug Administration
CMC Strategy Forum Japan 2015 9-10 November 2015 Piyanan Boonprasirt Bureau of Drug Control Thailand Food and Drug Administration 1 1. Background 2. Organization Chart 3. Biological Products 4. Regulation
More informationSupply Chain Supplier Quality Management. Nicholas Violand, Investigator/Drug Specialist US FDA, New Jersey District
Supply Chain Supplier Quality Management Nicholas Violand, Investigator/Drug Specialist US FDA, New Jersey District 1 Overview Product Life Cycle Maintaining Quality in Supply Chain FDA and ICH Guidances
More informationSubmission of comments on Guideline on Similar Biological Medicinal Products (CHMP/437/04 Rev1)
October 31, 2013 Submission of comments on Guideline on Similar Biological Medicinal Products (CHMP/437/04 Rev1) Comments from: Name of organisation or individual Biotechnology Industry Organization (BIO)
More informationVALIDATION OF ACTIVE PHARMACEUTICAL INGREDIENTS
VALIDATION OF ACTIVE PHARMACEUTICAL INGREDIENTS Second Edition Ira R. Berry Daniel Harpaz Editors ###5 Health Group *> MS-GHOUF Company Your Enterprise Solution for Global Healthcare Knowledge Denver,
More informationChapter 2 The Regulatory Environment
Chapter 2 The Regulatory Environment The relevance and importance of the regulatory environment cannot be overemphasized. 2.1 Introduction This chapter introduces the regulatory environment in which new
More informationGuideline on the Regulation of Therapeutic Products in New Zealand
Guideline on the Regulation of Therapeutic Products in New Zealand Part 10: Requirements for information for prescribers and consumers Edition 7.0 March 2017 Section 1: Legislation Section summary This
More informationChin Koerner Executive Director US Regulatory and Development Policy
Chin Koerner Executive Director US Regulatory and Development Policy Novartis Pharmaceuticals Corporation 1700 Rockville Pike Suite 510 Rockville, MD 20852 Tel 301.468.5607 Fax 301.468.5614 Email: Chin.Koerner@novartis.com
More informationINFORMATION ON JAPANESE REGULATORY AFFAIRS
2017 INFORMATION ON JAPANESE REGULATORY AFFAIRS Regulatory Information Task Force Japan Pharmaceutical Manufacturers Association Pharmaceutical Administration and Regulations in Japan Japan Pharmaceutical
More informationPharmaceutical Compounding Sterile and Nonsterile Preparations. Jeanne Sun, PharmD
Pharmaceutical Compounding Sterile and Nonsterile Preparations Jeanne Sun, PharmD Agenda Legal Framework Overview Pharmaceutical Compounding Nonsterile Preparations Pharmaceutical Compounding
More informationEUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL QUESTIONS. and ANSWERS
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, F2/SM D (2008) QUESTIONS and ANSWERS The rules governing medicinal products in the European Union VOLUME 2 NOTICE
More informationBest Practices In Pharmaceutical Formulation Development
1 Best Practices In Pharmaceutical Formulation Development 18-05-2018 2 Who are we? Your partner in achieving excellence Sidvim provides experience based, specialized consultancy services across all functional
More informationThe Role of Chemists in the FDA Drug Approval Process
The Role of Chemists in the FDA Drug Approval Process 231 st ACS National Meeting Atlanta, GA M. Scott Furness, Ph.D. March 26, 2006 Introduction Presentation Outline FDA Organization CDER Organization
More informationLinking Regulatory Commitments to Post Approval Changes Robert Iser
Linking Regulatory Commitments to Post Approval Changes Robert Iser Senior Scientific Advisor (acting) Office of Process & Facilities / OPQ / CDER IFPAC 2015 Product Lifecycle and QA January 27 th, 2015
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationUpdate on GCC Region. 8 May Prof. Saleh Bawazir Vice President for Drug Affairs Saudi Food and Drug Authority Riyadh, Saudi Arabia
Update on GCC Region ICH-GCG Meeting, Brussels 8 May 2007 Prof. Saleh Bawazir Vice President for Drug Affairs Saudi Food and Drug Authority Riyadh, Saudi Arabia 1 Three meetings were conducted since November
More informationCATEGORY Advertising. CATEGORY Biopharmaceutics. CATEGORY Biosimilarity
CATEGORY Advertising Guidance Agenda: New & Guidances CDER is Planning to Publish During Calendar Year 2016 (See the Good Guidance Practices (GGPs) regulation on this Web page or 21 CFR 10.115 for details
More informationValidation/Verification of Test Methods An FDA Perspective. Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness
Validation/Verification of Test Methods An FDA Perspective Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness FD & C Act Overview Definition of drugs What cgmps are Finished Pharmaceuticals cgmp
More informationThe FDA Just Arrived... Are You Ready? Presented By Sandra Lueken Sr. Director, Quality AstraZeneca Biologics
The FDA Just Arrived... Are You Ready? Presented By Sandra Lueken Sr. Director, Quality AstraZeneca Biologics Objectives Review Quality Systems Audit Approach and cgmp fundamentals Logistical Audit Preparation
More informationRegulatory Starting Materials An FDA Perspective
Regulatory Starting Materials An FDA Perspective Kasturi Srinivasachar Branch Chief (Acting), New Drug API Division Office of New Drug Products, OPQ/CDER/ FDA 1 CDER Reorganization Office of Pharmaceutical
More informationPharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act
Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance U.S. Department of Health and Human Services Food and Drug Administration Center for
More informationReview of fees payable under the Medicines Regulations 1984
Review of fees payable under the Medicines Regulations 1984 Consultation document Medsafe March 2018 Page 1 of 19 Contents INTRODUCTION... 3 Purpose and scope... 3 Background... 3 Why are the fees being
More informationPublic release of clinical information in drug submissions and medical device applications
Public release of clinical information in drug submissions and medical device applications Health Products and Food Branch March 10, 2017 Health Canada is the federal department responsible for helping
More informationOREGON HEALTH AUTHORITY DRUG USE REVIEW/PHARMACY AND THERAPEUTICS COMMITTEE. OPERATING PROCEDURES Updated: March 2018
OREGON HEALTH AUTHORITY DRUG USE REVIEW/PHARMACY AND THERAPEUTICS COMMITTEE OPERATING PROCEDURES Updated: March 2018 MISSION: To encourage safe, effective, and innovative drug policies that promote high
More informationSonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for Drug Evaluation and Research Food and Drug Administration
FDA Perspective on MedDRA Coding Quality in Post marketing Safety Reports European Informal MedDRA User Group Webinar Sonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for
More informationOverview of Regulatory Requirements for API and Formulations
Overview of Regulatory Requirements for API and Formulations Sangeeta Sardesai 4-Dec-2010 Definition - Regulatory Requirement The restrictions, licenses, and laws applicable to a product or business, imposed
More informationBioresearch Monitoring Inspections in Vitro Diagnostics Devices
Seite 1 von 7 U.S. Food and Drug Administration Protecting and Promoting Your Health Bioresearch Monitoring Inspections in Vitro Diagnostics Devices TABLE OF CONTENTS Introduction Nature, Scope, & Purpose
More informationCenter for Drug Evaluation and Research; Prescription Drug Labeling Improvement and. Enhancement Initiative; Request for Comments and Information
4160-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Parts 201, 314, and 601 [Docket No. FDA-2013-N-0059] Center for Drug Evaluation and Research; Prescription Drug Labeling
More informationGUIDANCE DOCUMENT Master Files (MFs) - Procedures and Administrative Requirements
GUIDANCE DOCUMENT Master Files (MFs) - Procedures and Administrative Requirements Published by authority of the Minister of Health Initial Draft Date 2008/08/05 Revision Date 2016/02/05 Effective Date
More informationGuidance for Industry Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act
Guidance for Industry Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act DRAFT GUIDANCE This guidance document is being distributed for comment purposes only.
More informationConditional Early Approval System for Innovative Medical Device Products (Fast-Break Scheme)
PSEHB Notification No. 0731-1 July 31, 2017 To: Prefectural Governors Director-General of the Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare (Official seal
More informationPharmacovigilance System in Russia and the EAEU
Pharmacovigilance System in Russia and the EAEU Authors: Sergey Simeniv CEO X7 Research, CRO; Olga Latysheva Head of Pharmacovigilance Department X7 Research, CRO; Dmitry Kryuchkov Executive Director X7
More informationAugust 2018: Questions & Answers Botswana Medicines Regulatory Authority
S A Pharmaceutical Regulatory Affairs Association P O Box 2909 Randburg 2125 R.S.A. Telephone: + 27 (0) 11 852 5252 Telefax: + 27 (0) 865044927 Date: 06 August 2018 To: Chief Executive Officer: Botswana
More informationICH Q11 Development & manufacture of drug substances
ICH Q11 Development & manufacture of drug substances Keith McDonald Group Manager Medicines & Healthcare products Regulatory Agency (UK) 2011 ICH International Conference on Harmonisation of Technical
More informationTable of Contents. Legal Notices... 61
Notice This manual provides information to excipient manufacturers who intend to participate in the United States Pharmacopeia Ingredient Verification Program for Excipients (USP IVP-E or Program). The
More informationMedical Device Labeling HealthPack 2004 Program
Medical Device Labeling HealthPack 2004 Program Elizabeth Kempen Overview Regulatory Agencies and Pathways Labeling Regulations General Medical Device Labeling Requirements Electronic Labeling FDA s Current
More information